Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world pharmacokinetics and pharmacodynamics of eculizumab in PNH
NL-OMON48010Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Radboud University Medical Center. Primary endpoints: Clearance and Volume of distribution. Started Feb 2021; status: active, not recruiting.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON48010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48010.